Revier Therapeutics secures €6 million in seed financing, led by KHAN Technology Transfer Fund II, to develop innovative therapies for cardiometabolic disease.
Amount Raised
€6 Million
Round Type
Seed
HeidelbergBiotechnologyHealth CareTherapeuticsInvestors
Description
Revier Therapeutics has announced the closing of €6 million in seed financing to pioneer class IIa histone deacetylases for treating cardiometabolic diseases. The funding will enhance the company's pipeline, focusing on heart failure and cardiovascular disease. This financing was supported by multiple investors, including KHAN Technology Transfer Fund II. The company's mission is to deliver impactful and long-term solutions for patients.
Quick answer
Revier Therapeutics raised €6 Million in a Seed round, dated August 25, 2026. Investors: High Tech Gründerfonds, Khan Technology Transfer Fund Ii, VORNvc and Private Investors Through Revier Invest Heidelberg. Revier Therapeutics is based in Heidelberg, Baden Württemberg, Germany.
- How much did Revier Therapeutics raise?
- Revier Therapeutics raised €6 Million in a Seed round on August 25, 2026.
- Who invested in Revier Therapeutics?
- High Tech Gründerfonds, Khan Technology Transfer Fund Ii, VORNvc and Private Investors Through Revier Invest Heidelberg are named as investors in this round.
- What does Revier Therapeutics do?
- Revier Therapeutics has established the first therapeutic approach to selectively target Class IIa HDACs for the treatment of cardiometabolic diseases.
- Where is Revier Therapeutics based and how big is it?
- Revier Therapeutics is based in Heidelberg, Baden Württemberg, Germany.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Revier Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Atrium Therapeutics raised $5.2M (Post-IPO Equity) on October 9, 2026.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Atrium Therapeutics raised $50M (Post-IPO Equity) on October 8, 2026.
- Vaxcyte, Inc. raised $1B (Convertible Note) on October 7, 2026.
- ADC Therapeutics raised $87M (Post-IPO Equity) on October 7, 2026.
- FibroBiologics raised $1.2M on October 7, 2026.
Who to call at Revier Therapeutics, and when
A new round usually means Revier Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Revier Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Revier Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Revier Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Revier Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Revier Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.